ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Accurate, reliable measurement of ulcers and polyps during endoscopy can improve disease assessment and tracking for people with Crohn’s disease and ulcerative colitis and may better align visual findings with symptoms and biomarkers like fecal calprotectin.
If validated, a laser-based tool could reduce variability from visual estimates and snare-based sizing used in routine colonoscopies.
Who Should Pay Attention
Patients with Crohn's disease or ulcerative colitis; gastroenterologists and endoscopists; researchers studying endoscopic measurement methods and disease activity biomarkers.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment3,000 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a prospective observational clinical trial testing AccuMeasure, a laser-based measurement tool used during standard-of-care gastrointestinal endoscopies to measure lesion and polyp size.
The study will compare AccuMeasure readings to visual estimation, snare-based sizing, and established endoscopic scores (SES-CD, CDEIS, Mayo endoscopic score) and correlate measurements with symptomatic indices (CD PRO2, partial Mayo) and fecal calprotectin. Enrollment is planned at CHUM in Montreal and the study is recruiting adults undergoing GI endoscopy.
Study procedures occur during routine endoscopy and do not change clinical care; investigators will record both traditional clinical size estimates and AccuMeasure readings during the same procedure.
Key outcomes include validity and reliability metrics (correlation coefficient, ICC), equivalence testing with endoscopic disease-activity scales, and relative inaccuracy comparisons versus visual and snare-based measurements. The trial is observational and registered on ClinicalTrials.gov.
Keep In Mind
This record describes a planned observational study and does not present study results. Outcomes focus on correlation and reliability metrics collected during routine endoscopies at a single center (CHUM).
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
Trial IDNCT07770425
Study typeObservational
Enrollment3,000 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 18, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Intestinal Ultrasound Guided Management in Inflammatory Bowel Disease
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
Evaluation of the Accuracy of Immunostaining of Claudin 2 to Detect Active or Inactive Inflammation in Endoscopic Biopsies of IBD
Patients and clinicians care about objective, reliable ways to tell if intestinal inflammation is truly healed because histologic healing predicts outcomes.